BRPI0817396C8 - composição farmacêutica para tratar deficiência de vitamina b¹² - Google Patents

composição farmacêutica para tratar deficiência de vitamina b¹²

Info

Publication number
BRPI0817396C8
BRPI0817396C8 BRPI0817396A BRPI0817396A BRPI0817396C8 BR PI0817396 C8 BRPI0817396 C8 BR PI0817396C8 BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 A BRPI0817396 A BR PI0817396A BR PI0817396 C8 BRPI0817396 C8 BR PI0817396C8
Authority
BR
Brazil
Prior art keywords
deficiency
vitamin
pharmaceutical composition
individual
treating
Prior art date
Application number
BRPI0817396A
Other languages
English (en)
Portuguese (pt)
Inventor
Castelli Cristina
Kragie Laura
Original Assignee
Emisphere Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40591491&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0817396(C8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc
Publication of BRPI0817396A2 publication Critical patent/BRPI0817396A2/pt
Publication of BRPI0817396B1 publication Critical patent/BRPI0817396B1/pt
Publication of BRPI0817396B8 publication Critical patent/BRPI0817396B8/pt
Publication of BRPI0817396C1 publication Critical patent/BRPI0817396C1/pt
Publication of BRPI0817396C8 publication Critical patent/BRPI0817396C8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0817396A 2007-11-02 2008-10-31 composição farmacêutica para tratar deficiência de vitamina b¹² BRPI0817396C8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98489807P 2007-11-02 2007-11-02
US60/984,898 2007-11-02
US2010808P 2008-01-09 2008-01-09
US61/020,108 2008-01-09
US8356608P 2008-07-25 2008-07-25
US61/083,566 2008-07-25
PCT/US2008/082064 WO2009059188A1 (en) 2007-11-02 2008-10-31 Method of treating vitamin b12 deficiency

Publications (5)

Publication Number Publication Date
BRPI0817396A2 BRPI0817396A2 (pt) 2015-04-07
BRPI0817396B1 BRPI0817396B1 (pt) 2019-04-24
BRPI0817396B8 BRPI0817396B8 (pt) 2020-02-04
BRPI0817396C1 BRPI0817396C1 (pt) 2020-11-17
BRPI0817396C8 true BRPI0817396C8 (pt) 2021-05-25

Family

ID=40591491

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0817396A BRPI0817396C8 (pt) 2007-11-02 2008-10-31 composição farmacêutica para tratar deficiência de vitamina b¹²

Country Status (18)

Country Link
US (3) US8022048B2 (enExample)
EP (1) EP2215047B1 (enExample)
JP (1) JP5555634B2 (enExample)
KR (1) KR101344369B1 (enExample)
CN (1) CN101952241B (enExample)
AU (1) AU2008318423B2 (enExample)
BR (1) BRPI0817396C8 (enExample)
CA (1) CA2704780C (enExample)
CL (1) CL2010000434A1 (enExample)
CO (1) CO6280475A2 (enExample)
DK (1) DK2215047T3 (enExample)
ES (1) ES2443817T3 (enExample)
MX (1) MX2010004716A (enExample)
NZ (1) NZ585080A (enExample)
PL (1) PL2215047T3 (enExample)
PT (1) PT2215047E (enExample)
RU (1) RU2469728C2 (enExample)
WO (1) WO2009059188A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110039930A1 (en) * 2009-08-03 2011-02-17 Emisphere Technologies, Inc. Fast-acting naproxen composition with reduced gastrointestinal effects
KR20130026429A (ko) * 2010-02-24 2013-03-13 에미스페어 테크놀로지스, 인코포레이티드 경구 ｂ12 치료요법
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
US8805208B2 (en) * 2012-02-03 2014-08-12 Tyco Electronics Subsea Communications Llc System and method for polarization de-multiplexing in a coherent optical receiver
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
HRP20190489T1 (hr) 2012-03-22 2019-05-03 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
US9603812B2 (en) 2013-04-11 2017-03-28 Richard Louis Price Treatment of autistic spectrum disorder
US20170348417A1 (en) 2013-04-11 2017-12-07 Richard Louis Price Treatment of attention deficit disorders and associated symptoms
US9211284B2 (en) 2013-04-11 2015-12-15 Richard Louis Price Diagnosis and treatment of P.R.I.C.E. syndrome
US10098848B2 (en) 2013-04-11 2018-10-16 Richard Louis Price Inositol-containing comestible units and methods of treatment using the same
US20140309270A1 (en) 2013-04-11 2014-10-16 Richard Louis Price Diagnosis and treatment of a form of autistic spectrum disorder
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
KR102393596B1 (ko) 2016-04-22 2022-05-04 리셉터 홀딩스, 인크. 속효성 식물-계 의약 화합물 및 영양 보충제
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
AR113749A1 (es) * 2017-10-05 2020-06-10 Receptor Holdings Inc Formulaciones cannabinoides sintéticas y a base de plantas de inicio rápido y acción prolongada
BR112020006690A2 (pt) * 2017-10-05 2020-10-06 Receptor Holdings, Inc. composições à base de plantas com biodisponibilidade aprimorada
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
AR117118A1 (es) 2018-11-19 2021-07-14 Receptor Holdings Inc Aminoácidos grasos n-acilados para reducir la variabilidad de absorción en composiciones a base de cannabinoides

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665379A (en) 1990-09-28 1997-09-09 Pharmacia & Upjohn Aktiebolag Lipid particle forming matrix, preparation and use thereof
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6274564B1 (en) * 1996-09-18 2001-08-14 William J. Sarill Compositions of cobalamin and related corrinoids, and uses thereof
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6255294B1 (en) * 1998-12-28 2001-07-03 Allergy Limited Cyanocobalamin (vitamin B12) treatment in allergic disease
NZ534409A (en) 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
EP1535625B1 (en) 1999-04-05 2014-01-08 Novartis AG Composition containing n-(5-chlorosalicyloyl)-8-aminocaprylic acid and salmon calcitonin
CA2402719C (en) 2000-03-21 2012-03-20 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides via a dicarboxylate intermediate
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
CA2446929C (en) 2001-06-01 2013-04-09 Novartis Ag Orally administering parathyroid hormone and calcitonin
WO2003015822A1 (en) 2001-08-17 2003-02-27 Novartis Ag 5-cnac as oral delivery agent for parathyroid hormone fragments
US20050054557A1 (en) 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (es) 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
RU2359698C2 (ru) * 2002-09-13 2009-06-27 Сайдекс, Инк. Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
WO2004087640A1 (en) 2003-04-04 2004-10-14 Dsm Ip Assets B.V. Process for the manufacture of n-alkoxalyl-alaninates
US6938439B2 (en) 2003-05-22 2005-09-06 Cool Clean Technologies, Inc. System for use of land fills and recyclable materials
JP3924616B2 (ja) 2003-06-30 2007-06-06 独立行政法人物質・材料研究機構 微小サイズの温度感知素子を用いる温度計測方法
EP1643978A1 (en) 2003-07-04 2006-04-12 Nycomed Danmark A/S Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
PT1651248E (pt) 2003-07-11 2009-11-10 Novartis Ag Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
PL1651249T3 (pl) 2003-07-23 2013-04-30 Novartis Ag Zastosowanie kalcytoniny w zapaleniu kości i stawów
SG153039A1 (en) 2004-05-06 2009-06-29 Emisphere Tech Inc Crystalline polymorphic forms of monosodium n-[8- (2hydroxybenzoyl)amino]caprylate
WO2006020291A2 (en) * 2004-08-02 2006-02-23 Bebaas, Inc. Vitamin b12 compositions
JP2008509933A (ja) 2004-08-13 2008-04-03 エミスフェアー・テクノロジーズ・インク 送達剤のマイクロ粒子またはナノ粒子を含む医薬製剤
US20060116334A1 (en) 2004-12-01 2006-06-01 Curt Hendrix Folate based composition for treatment of the cardiovascular system
GB0427600D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
GB0427603D0 (en) 2004-12-16 2005-01-19 Novartis Ag Organic compounds
CA2626029A1 (en) 2005-11-04 2007-05-18 Genta Incorporated Pharmaceutical gallium compositions and methods

Also Published As

Publication number Publication date
US8022048B2 (en) 2011-09-20
NZ585080A (en) 2012-05-25
AU2008318423B2 (en) 2013-12-05
JP5555634B2 (ja) 2014-07-23
US20130040910A1 (en) 2013-02-14
CN101952241A (zh) 2011-01-19
BRPI0817396A2 (pt) 2015-04-07
EP2215047A1 (en) 2010-08-11
DK2215047T3 (da) 2014-02-03
AU2008318423A1 (en) 2009-05-07
US20100016255A1 (en) 2010-01-21
CN101952241B (zh) 2014-06-11
WO2009059188A1 (en) 2009-05-07
RU2469728C2 (ru) 2012-12-20
MX2010004716A (es) 2010-12-17
HK1146480A1 (en) 2011-06-10
EP2215047B1 (en) 2013-11-20
RU2010118423A (ru) 2011-12-10
KR101344369B1 (ko) 2013-12-24
CA2704780A1 (en) 2009-05-07
CO6280475A2 (es) 2011-05-20
EP2215047A4 (en) 2010-11-10
KR20100126263A (ko) 2010-12-01
PL2215047T3 (pl) 2014-05-30
US8557792B2 (en) 2013-10-15
BRPI0817396C1 (pt) 2020-11-17
BRPI0817396B8 (pt) 2020-02-04
BRPI0817396B1 (pt) 2019-04-24
US8288360B2 (en) 2012-10-16
JP2011502997A (ja) 2011-01-27
PT2215047E (pt) 2014-01-20
ES2443817T3 (es) 2014-02-20
CA2704780C (en) 2014-06-10
CL2010000434A1 (es) 2011-01-28
US20110293589A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
BRPI0817396C8 (pt) composição farmacêutica para tratar deficiência de vitamina b¹²
BRPI0415953A (pt) formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
NZ744233A (en) Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
ATE494889T1 (de) Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
BR112018068784A2 (pt) método para o tratamento de leucemia
CL2021003474A1 (es) Producto farmacéutico para terapia enzimática para tratamiento de homocistinuria
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
CL2021000882A1 (es) Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia.
AR091724A1 (es) Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica
MX2013014071A (es) Combinacion de tratamiento de sinergia para el tratamiento del carcinoma de celula escamosa de cabeza y cuello.
UA115250C2 (uk) Фармацевтичні комбінації
BR112015023368A2 (pt) método de tratamento de deficiência de vitamina b12
NZ701274A (en) Oral b12 therapy
BR112018074434A2 (pt) composições farmacêuticas compreendendo safinamida
BR112023023715A2 (pt) Pluralidade de partículas compreendendo tasquinimod, composição farmacêutica, unidade de dosagem farmacêutica, uso da pluralidade de partículas ou da composição farmacêutica, e, método para o tratamento do câncer
BRPI0517241A (pt) composição farmacêutica, e, método para preparar a mesma
BR112018072583A2 (pt) composição farmacêutica de comprimido em comprimido estável
BR112018067674A2 (pt) compostos derivados de carbamato, processos para preparação dos mesmos e seus usos.
AR108792A1 (es) Composiciones que comprenden timolol
AR072871A1 (es) Combinacion terapeutica que comprende un inhibidor de aurora quinasa y un agente antineoplasico, composicion farmaceutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 25/04/2019 QUANTO AO INVENTOR.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2520 DE 24/04/2019 QUANTO AO PRAZO DE VALIDADE.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2746 DE 22-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.